GP681 clinical trials
Also written GP681.
How each study uses GP681 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the GP681 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test GP681, phase 3 first.
- Jul 2027Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against InfluenzaPhase 3 · Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Studies
Open first, then newest update. How each study uses GP681 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against InfluenzaRecruitingPhase 3Jiangxi Qingfeng Pharmaceutical Co. Ltd.NCT06574503Written as GP681 40mg
- Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza ComplicationsRecruitingPhase 3Jiangxi Qingfeng Pharmaceutical Co. Ltd.NCT06573008Written as GP681 40mg
- Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male SubjectsCompletedPhase 1Jiangxi Qingfeng Pharmaceutical Co. Ltd.NCT06678542Written as GP681 tablet
- GP681 in Volunteers With Hepatic Impairment Compared With Healthy VolunteersCompletedPhase 1Jiangxi Qingfeng Pharmaceutical Co. Ltd.NCT05814926Written as GP681
- To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus InfectionCompletedPhase 3Jiangxi Qingfeng Pharmaceutical Co. Ltd.NCT05474755Written as GP681 40mg
- A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy VolunteersCompletedPhase 1Jiangxi Qingfeng Pharmaceutical Co. Ltd.NCT05789342Written as GP681
- A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute InfluenzaCompletedPhase 2Jiangxi Qingfeng Pharmaceutical Co. Ltd.NCT04736758Written as GP681 tablet
- A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male VolunteersCompletedPhase 1Jiangxi Qingfeng Pharmaceutical Co. Ltd.NCT05103241Written as [14C] GP681
- Evaluation the Safety and Tolerance of GP681 Tablets in Healthy SubjectsCompletedPhase 1Jiangxi Qingfeng Pharmaceutical Co. Ltd.NCT04729764Written as GP681 Tablet